←
Ramy Sedhom, MD, FASCO5,356 posts
Ramy Sedhom, MD, FASCO avatar✓

Ramy Sedhom, MD, FASCO ✓

@ramsedhom

Director, Center for Cancer & Aging at Penn Dreamer / Developer of Systems focused on Patient-Centered Care

◷ Joined November 2013▧ 257 Photos and videos
Common Sense Oncology avatar
⟳ Ramy Sedhom, MD, FASCO retweeted
Common Sense Oncology@csoncol·Nov 5

Join CSO on November 16th for a critical appraisal of the RASolute 302 trial, followed by a discussion of how the pricing of daraxonrasib will impact patient access. Where: Online (Zoom) When: Monday, November 16, 2026 at 2:00 pm (EST) / 1:00 pm (CST) / 12:00 pm (MST) Speakers: Dr. Ian Tannock, Dr. Chris Booth, Dr. Sharlene Gill, Carolyn Taylor, Dr. Ramy Sedhom Register now: tinyurl.com/hr3jsnxc #CommonSenseOncology #CancerCare #Daraxonrasib

Post attachment
Yara Abdou, MD, MSCR avatar
⟳ Ramy Sedhom, MD, FASCO retweeted
Yara Abdou, MD, MSCR@YAbdouMD·Oct 28

Proudly voting for @minasedrakmd and @RManochakian !! Incredible physicians and wonderful human beings. So proud to see fellow Middle Eastern oncologists leading the way! Please vote and show your support🗳️

Post attachment
Mina S. Sedrak avatar
⟳ Ramy Sedhom, MD, FASCO retweeted
Mina S. Sedrak@minasedrakmd·Oct 28

Voting for the ASCO Election is now open. I am honored to be running as one of the candidates for the ASCO Nominating Committee. Visit asco.org/election to learn more about the candidates and place your vote!

Post attachment
Mina S. Sedrak avatar
⟳ Ramy Sedhom, MD, FASCO retweeted
Mina S. Sedrak@minasedrakmd·Oct 28

Thank you for sharing! Grateful to @NCIDirector @theNCI for this new R01! Many older adults struggle to regain strength after transplant. We hope this work helps them recover faster and live well. Grateful for my Co-PIs @ArmenianSaro and Kirsten Ness. Both are helping bring concepts from Pediatrics Oncology to #GeriOnc.

Post attachment
Dr Sarah Sammons avatar
⟳ Ramy Sedhom, MD, FASCO retweeted
Dr Sarah Sammons@drsarahsam·Oct 26

First prospective switch trial of Top1 ADC post Top1 ADC in MBC. 0-8% ORR Switching target with same payload simply does not work. Resistance is in payload. Let’s stop talking about “sequencing”. It simply does not work. We need new payloads. #MBC #BCSM #ESMO26

Post attachmentPost attachmentPost attachment
Mohamed Osman avatar
⟳ Ramy Sedhom, MD, FASCO retweeted
Mohamed Osman@MHosmanMD·Oct 22

Really enjoyed this conversation! Thanks @ramsedhom for such a thoughtful and insightful discussion.

Mina S. Sedrak avatar
⟳ Ramy Sedhom, MD, FASCO retweeted
Mina S. Sedrak@minasedrakmd·Oct 21

“Chemo brain” is one of the most common things my patients ask me about. We still have no proven drug to treat it. In our small phase II trial, breast cancer survivors with cognitive complaints took oxaloacetate for 8 weeks. Every participant who completed the study reported improvement in cognition, along with less fatigue and better physical function. It’s an early signal, not an answer. A randomized, placebo-controlled trial is the next step. Led by Dr. Patti Ganz, with thanks to @BCRFcure. Out now in @JCOOA_ASCO. doi.org/10.1200/OA-26-00063 #bcsm

Post attachment
David Einstein avatar
⟳ Ramy Sedhom, MD, FASCO retweeted
David Einstein@davidjeinstein·Oct 21

Super insightful piece. With Daniel Sentana and @CaPsurvivorship, we’ve had similar debates re the meaning of healthcare contact days in advanced prostate cancer.